Bio-Techne Corporation’s acquired all the stock of Trevigen Inc. for cash.
Bio-Techne provides high-quality reagents, instruments, custom manufacturing, and testing services to researchers in Life Sciences and Clinical Diagnostics.
Trevigen offers world class cell stress, DNA damage, and physiologic cell culture products, and contract services for the biotech research community.
The Trevigen products complement Bio-Techne’s current product portfolio and make it easier to reach customers interested in products to better understand cell behavior and genotoxic events on cells.
Having a broader array of products will both serve Trevigen’s customers more efficiently, as well as provide additional channels for Trevigen’s products in the global market.
Crosstree Capital Partners acted as exclusive financial advisor to Trevigen.